The present invention relates to processes for the preparation of empagliflozin. In particular, the present invention relates to the preparation of empagliflozin and intermediates thereof. The present invention also relates to co-crystal of empagliflozin and amino acid and amorphous form of empagliflozin.

A compound, composition, or method for treating cancer is disclosed. The compound (that can be used in the composition and/or method) can include ##STR00001##
or pharmaceutically acceptable salts or solvates thereof. R.sup.1a-R.sup.1d, R.sup.2-R.sup.3 (and R.sup.4 where applicable), and A---B can be as defined herein.

A compound, composition, or method for treating cancer is disclosed. The compound (that can be used in the composition and/or method) can include ##STR00001##
or pharmaceutically acceptable salts or solvates thereof. R.sup.1a-R.sup.1d, R.sup.2-R.sup.3 (and R.sup.4 where applicable), and A---B can be as defined herein.

The present disclosure describes methods for silylating aromatic organic substrates, and associated chemical systems, said methods comprising or consisting essentially of contacting the aromatic organic substrate with a mixture of (a) at least one organosilane and (b) at least one strong base, under conditions sufficient to silylate the aromatic substrate.

The present disclosure describes methods for silylating aromatic organic substrates, and associated chemical systems, said methods comprising or consisting essentially of contacting the aromatic organic substrate with a mixture of (a) at least one organosilane and (b) at least one strong base, under conditions sufficient to silylate the aromatic substrate.

The present disclosure describes methods for silylating aromatic organic substrates, and associated chemical systems, said methods comprising or consisting essentially of contacting the aromatic organic substrate with a mixture of (a) at least one organosilane and (b) at least one strong base, under conditions sufficient to silylate the aromatic substrate.

The invention relates to a method for the preparation of cannabidiol and an intermediate for the preparation of cannabidiol, wherein two intermediates are obtained, namely a silylated olivetol and a silylated olivetol (2) and brominated olivetol (4) which are stable, storable and which do not have undesirable properties or byproducts.

The invention relates to a method for the preparation of cannabidiol and an intermediate for the preparation of cannabidiol, wherein two intermediates are obtained, namely a silylated olivetol and a silylated olivetol (2) and brominated olivetol (4) which are stable, storable and which do not have undesirable properties or byproducts.

The invention relates to a method for the preparation of cannabidiol and an intermediate for the preparation of cannabidiol, wherein two intermediates are obtained, namely a silylated olivetol and a silylated olivetol (2) and brominated olivetol (4) which are stable, storable and which do not have undesirable properties or byproducts.

Provided are a 4-hydroxystyrene solution with high purity and good storage stability that is suitable as a source for producing a 4-hydroxystyrene polymer on a commercial scale, and a method of producing the solution. The method of producing a 4-hydroxystyrene solution of the present invention includes the following steps (i) to (iv): (i) deprotection step for contacting 4-acetoxystyrene with a base in a solvent to produce 4-hydroxystyrene; (ii) neutralization step for adding an acid to the solution containing 4-hydroxystyrene after deprotection to neutralize the solution; (iii) step for washing the solution containing 4-hydroxystyrene after neutralization with water; and (iv) solvent replacement step for adding a solvent that can dissolve 4-hydroxystyrene to the solution containing 4-hydroxystyrene followed by distillation at 40° C. or lower to remove other components than 4-hydroxystyrene and excess solvent.